- Poster presentation
- Open Access
Comparison of the efficacy at 48 weeks of first-line antiretroviral treatment for HIV infection in 1998 and 2006: a multicentric investigation
© Sozio et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Viral Suppression
- Immune Parameter
- Multicentric Investigation
- Immune Recovery
- Therapy Modification
HAART efficacy for HIV-infected patients increased over time as more drugs and novel drug classes became available. It is not yet fully clear, however, which factors are most relevant to the increased success of more recent first-line regimens. We therefore planned to retrospectively investigate the efficacy of first-line regimens prescribed at our Institutions in 1998 and 2006.
Clinical records of all consecutive patients starting their first line HAART during 1998 and 2006 were evaluated for: age, sex, risk factors, co-morbidities, CDC stage, treatment adherence, record of any toxic event and/or therapy modification, basal, 24- and 48-week CD4 T-cell counts, HIV viremia, glycaemia, total cholesterol, triglycerides. All statistical analyses were performed using the Stata 10 software.
146 patients were included, 76.0% males, with a mean age of 38.2 years, mean basal CD4 T-cells 250.3/mm3 and HIV viremia 5.66 log10 copies/mL; 67 patients were considered in 1998, 79 in 2006, without any significant difference for basal values. HIV suppression at 48 weeks was observed in 59.1% of patients in 1998 and in 88.6% in 2006 (p < 0.001). Multivariate logistic regression demonstrated that viral suppression was independently associated only with 48-week adherence (OR 20.6, CI 5.9–71.9, p < 0.001) and being treated in 2006 (OR 8.6, CI 2.4–30.6, p < 0.001). Moreover, adherence to HAART was significantly associated with better immune recovery at 24 weeks (p = 0.01) and 48 weeks (p = 0.02). Neither demographic, nor basal immune parameters, nor adverse events significantly altered the likelihood of viral suppression.
Our results indicate that after 48 weeks, patients treated with more recent first-line regimens have better chances of viral suppression and immune recovery than at the dawn of HAART. Adherence to therapy seems to be increased in parallel over time, and to be tightly associated with both outcomes. The independent association of better outcomes with the year of treatment and not with any other factor, including the incidence of adverse events, would suggest greater intrinsic potency of new HAART regimens.
This article is published under license to BioMed Central Ltd.